<code id='3237EA9B60'></code><style id='3237EA9B60'></style>
    • <acronym id='3237EA9B60'></acronym>
      <center id='3237EA9B60'><center id='3237EA9B60'><tfoot id='3237EA9B60'></tfoot></center><abbr id='3237EA9B60'><dir id='3237EA9B60'><tfoot id='3237EA9B60'></tfoot><noframes id='3237EA9B60'>

    • <optgroup id='3237EA9B60'><strike id='3237EA9B60'><sup id='3237EA9B60'></sup></strike><code id='3237EA9B60'></code></optgroup>
        1. <b id='3237EA9B60'><label id='3237EA9B60'><select id='3237EA9B60'><dt id='3237EA9B60'><span id='3237EA9B60'></span></dt></select></label></b><u id='3237EA9B60'></u>
          <i id='3237EA9B60'><strike id='3237EA9B60'><tt id='3237EA9B60'><pre id='3237EA9B60'></pre></tt></strike></i>

          fashion

          fashion

          author:explore    Page View:8
          Cigna Healthcare's logo on a phone
          Adobe

          CVS Health viewed Amy Bricker as a potential CEO. But she won’t be going to the health care conglomerate anytime soon.

          A federal appeals court has ruled Bricker, a former high-ranking executive at Cigna, cannot jump to CVS because it would violate her noncompete agreement that she signed while at Cigna. The appeals court’s decision backs up what a district court had previously ruled.

          advertisement

          The case is a prominent example of why the health care industry, and corporate America writ large, does not want noncompetes to go away. In April, the Federal Trade Commission approved a nationwide ban on most such agreements, which prevent workers from moving to other jobs, but companies and corporate lobbying groups have already sued to squash the ban.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more
          Unmasking the 'centricity' illusion in clinical trials
          Unmasking the 'centricity' illusion in clinical trials

          JoeRaedle/GettyImagesDuringmy25yearsworkinginclinicaltrialoperations,I’veseenthebiopharmaceuticalwor

          read more
          Activists slam private health insurers over coverage restrictions
          Activists slam private health insurers over coverage restrictions

          ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

          read more

          Campaign finance charge dropped from case against Sam Bankman

          FTXfounderSamBankman-FriedleavesFederalcourt,Wednesday,July26,2023,inNewYork.(APPhoto/MaryAltaffer)T